COMPANY

VBI Vaccines

HQ: Cambridge, MA source · vbivaccines.com ↗

FDA-approved therapeutic company Clinical Phase 2

Keywords: oncology infectious disease vaccine severe acute respiratory syndrome COVID-19 Middle East respiratory syndrome Hepatitis B Coronavirus Infections Hepatitis B Vaccines Vaccine Exposure During Pregnancy Glioblastoma Multiforme Covid19 Cytomegalovirus Infections Hepatitis B Vaccination VBI-2901a VBI-1901 VBI-2902a VBI-2905a VBI-2901e Sci-B-Vac™ VBI-1501A VBI-1501

Location: Cambridge, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

11Trials (company is sponsor)

Timeline

Nov 30, 2023 Trial start —: PREHEVBRIO Pregnancy Outcomes Registry source ↗
2023-03 Trial start Phase 1: Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901e With E6020 Adjuvant source ↗
Oct 5, 2022 Trial start Phase 1: Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a source ↗
Mar 15, 2021 Trial start Phase 1: Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a source ↗
Dec 14, 2017 Trial start Phase 3: Lot-to-lot Consistency of Sci-B-Vac™ in Adults source ↗
Dec 13, 2017 Trial start Phase 3: Immunogenicity and Safety of Sci-B-Vac® to Engerix-B® in Adults source ↗
Dec 6, 2017 Trial start Phase 1/Phase 2: Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects source ↗
Jun 23, 2016 Trial start Phase 1: Study to Evaluate Safety, Tolerability, and Immunogenicity of Candidate Human Cytomegalovirus Vaccine in Healthy Adults source ↗
Nov 1, 2015 Trial start Phase 4: A Study to Qualify an In-house Reference Standard Batch of Sci-B-Vac™ source ↗
Apr 18, 2014 Trial start Phase 3: Safety and Immunogenicity of Recombinant Hepatitis B Vaccine Sci-B-Vac® Compared to Engerix-B® source ↗
Mar 2, 2006 Trial start Phase 3: A Bridging Study: Comparing Two Lots of Sci-B-Vac™ and Engerix-B in Healthy Adults source ↗

Clinical trials (lead sponsor) 11

Record	Title	Phase	Status	Start	Primary completion
NCT06097312	PREHEVBRIO Pregnancy Outcomes Registry	Not listed	Withdrawn	Nov 30, 2023	Mar 31, 2032 (estimated)
NCT05548439	Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a	Phase 1	Completed	Oct 5, 2022	Jan 16, 2024 (actual)
NCT03382977	Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects	Phase 1/Phase 2	Terminated	Dec 6, 2017	Jul 30, 2025 (actual)
NCT04773665	Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a	Phase 1	Completed	Mar 15, 2021	Nov 14, 2022 (actual)
NCT05614245	Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901e With E6020 Adjuvant	Phase 1	Withdrawn	2023-03	2024-06 (estimated)
NCT04531098	A Bridging Study: Comparing Two Lots of Sci-B-Vac™ and Engerix-B in Healthy Adults	Phase 3	Completed	Mar 2, 2006	Dec 31, 2008 (actual)
NCT04209400	Safety and Immunogenicity of Recombinant Hepatitis B Vaccine Sci-B-Vac® Compared to Engerix-B®	Phase 3	Completed	Apr 18, 2014	Apr 20, 2015 (actual)
NCT04179786	A Study to Qualify an In-house Reference Standard Batch of Sci-B-Vac™	Phase 4	Completed	Nov 1, 2015	Feb 7, 2017 (actual)
NCT03408730	Lot-to-lot Consistency of Sci-B-Vac™ in Adults	Phase 3	Completed	Dec 14, 2017	Oct 1, 2019 (actual)
NCT03393754	Immunogenicity and Safety of Sci-B-Vac® to Engerix-B® in Adults	Phase 3	Completed	Dec 13, 2017	Apr 8, 2019 (actual)
NCT02826798	Study to Evaluate Safety, Tolerability, and Immunogenicity of Candidate Human Cytomegalovirus Vaccine in Healthy Adults	Phase 1	Completed	Jun 23, 2016	Sep 15, 2016 (actual)